FrancophonIA/ELRC3.0 huggingface dataset:
English: • If you have diarrhoea while taking diacerein, stop taking your medicine and contact your doctor to discuss which other treatments you can take.
Slovenian: • če med jemanjem diacereina opazite drisko, prenehajte jemati zdravilo in se posvetujte z zdravnikom o drugih zdravilih, ki bi jih lahko uporabljali;
English: These recommendations are based on the review of the benefits and risks of diacerein conducted by the EMA's Pharmacovigilance and Risk Assessment Committee (PRAC) and follow concerns raised by the French medicines agency (ANSM) about diacerein's gastro-intestinal and liver effects.
Slovenian: Priporočila temeljijo na pregledu koristi in tveganj, povezanih z diacereinom, ki ga je opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC) pri Evropski agenciji za zdravila, in so bila sprejeta potem, ko je francoska agencija za zdravila (ANSM) izrazila zaskrbljenost glede učinkov diacereina na prebavila in jetra.
English: However, following re-examination, the PRAC considered additional proposals to manage diacerein's risks and was satisfied that with new restrictions diacerein's benefits would outweigh its risks.
Slovenian: Nato je ob ponovnem pregledu odbor PRAC proučil dodatne predloge za obvladanje tveganj, povezanih z diacereinom, in je bil prepričan, da bodo z novimi omejitvami koristi diacereina večje od z njim povezanih tveganj.
English: Efficacy in the symptomatic treatment of osteoarthritis of the hip or knee was shown in published studies where diacerein was superior to placebo in relieving pain1-5.
Slovenian: Učinkovitost pri simptomatskem zdravljenju osteoartritisa kolka ali kolena je bila dokazana v objavljenih študijah, v katerih je bil diacerein učinkovitejši od placeba pri lajšanju bolečine1-5.
English: On 19 March 2014, the Co-ordination Group for Mutual Recognition and Decentralised ProceduresHuman (CMDh)1 endorsed recommendations to restrict the use of diacerein-containing medicines in order to manage the risks of severe diarrhoea and effects on the liver.
Slovenian: Usklajevalna skupina za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMDh)1 je 19. marca 2014 potrdila priporočila za omejitev uporabe zdravil, ki vsebujejo diacerein, da bi obvladali tveganja za hudo drisko in učinke na jetra.
English: The CMDh endorsed the PRAC's final recommendations to address these concerns and ensure that diacerein's benefits continue to outweigh its known risks.
Slovenian: Skupina CMDh je potrdila končna priporočila odbora PRAC, s katerimi naj bi zmanjšali ta tveganja in zagotovili, da bodo koristi diacereina še naprej večje od z njim povezanih znanih tveganj.
English: to 4 weeks, after which the recommended dose is 50 mg twice a day.
Slovenian: 50 mg na dan), kasneje pa je priporočeni odmerek 50 mg dvakrat na dan;
English: − diacerein is not recommended in patients aged 65 years or above.
Slovenian: − se diacerein ne priporoča pri bolnikih, starih 65 let ali več.
English: In addition, diacerein-containing medicines must now not be used in any patient with liver disease or a history of liver disease, and doctors should be monitoring their patients for early signs of liver problems.
Slovenian: Poleg tega se zdravila, ki vsebujejo diacerein, ne smejo več uporabljati pri nobenem bolniku, ki ima ali je kdaj imel bolezen jeter, zdravniki pa morajo bolnike spremljati glede zgodnjih znakov težav z jetri.
English: Following an EU-wide review of diacerein, its use has been restricted in order to minimise the risks of severe diarrhoea and liver problems.
Slovenian: Po pregledu diacereina, opravljenem v celotni EU, je bila uporaba tega zdravila omejena, da bi zmanjšali tveganja za hudo drisko in težave z jetri.
English: • If you are taking diacerein and you are 65 years or above, contact your doctor to discuss your treatment.
Slovenian: • če jemljete diacerein in ste stari 65 let ali več, se o zdravljenju posvetujte z zdravnikom;
English: − treatment should be stopped if diarrhoea occurs.
Slovenian: − je treba zdravljenje ob pojavu driske prekiniti;
English: • Diacerein should only be used to treat symptoms of osteoarthritis of the hip or knee and it is not recommended for rapidly progressive hip osteoarthritis.
Slovenian: • Diacerein se lahko uporablja samo za zdravljenje simptomov osteoartritisa kolka ali kolena, vendar se ne priporoča pri hitro napredujočem osteoartritisu kolka.
English: Your doctor will monitor your liver function on a regular basis and advise about the symptoms of liver problems (such as pruritus
Slovenian: Zdravnik bo redno spremljal delovanje vaših jeter in vas seznanil s simptomi težav z jetri (na primer pruritus (srbenje) in zlatenica).
English: Treatment should only be started by doctors experienced in treating osteoarthritis.
Slovenian: Zdravljenje smejo uvesti samo zdravniki, ki imajo izkušnje z zdravljenjem osteoartritisa.
English: • Diacerein should only be used for treating symptoms of osteoarthritis affecting the hip or knee.
Slovenian: • diacerein se lahko uporablja samo za zdravljenje simptomov osteoartritisa, ki prizadene kolk ali koleno;
English: Diacerein is a medicine used to treat joint diseases such as osteoarthritis (swelling and pain in the joints).
Slovenian: Diacerein je zdravilo, ki se uporablja za zdravljenje bolezni sklepov, kot je na primer osteoartritis (otekanje sklepov in bolečina v sklepih).
English: With regard to safety, loose stools or diarrhoea were the most frequently reported adverse events in clinical studies with diacerein at a dose of 100 mg per day.
Slovenian: Kar zadeva varnost, sta bila neželena učinka, o katerih so najpogosteje poročali v kliničnih študijah z diacereinom v odmerku 100 mg na dan, mehko blato in driska.
English: Diacerein is a slow-acting medicine of the class ‘anthraquinones' used to treat joint diseases such as osteoarthritis (swelling and pain in the joints).
Slovenian: Diacerein je počasi delujoče zdravilo, ki spada v skupino „antrakinonov“, ki se uporabljajo za zdravljenje bolezni sklepov, kot je na primer osteoartritis (otekanje sklepov in bolečina v sklepih).
English: • Treatment should only be started by doctors experienced in treating osteoarthritis.
Slovenian: • Zdravljenje naj uvede samo zdravnik, ki ima izkušnje z zdravljenjem osteoartritisa.
English: − it is advisable to start treatment with half the normal dose (i.e. 50 mg per day) for the first 2
Slovenian: − je priporočljivo, da se zdravljenje prva 2 do 4 tedne začne s polovico običajnega odmerka (tj. s
English: Elevated serum liver enzymes and cases of symptomatic acute hepatic injury have been reported in the post-marketing phase with diacerein.
Slovenian: V obdobju trženja diacereina so poročali o zvišanih ravneh jetrnih encimov v serumu in primerih simptomatske akutne poškodbe jeter.
English: • Diacerein must not be used in any patient with liver disease or a history of liver disease.
Slovenian: • Diacerein se ne sme uporabljati pri nobenem bolniku, ki ima ali je kdaj imel bolezen jeter.
English: Pavelka K, Trc T, Karpas K, Vítek P, Sedlacková M, Vlasáková V, Böhmová J, Rovenský J. The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee.
Slovenian: Pavelka, K., Trc, T., Karpas, K., Vítek, P., Sedlacková, M., Vlasáková, V., Böhmová, J., Rovenský, J., „Učinkovitost in varnost diacereina pri zdravljenju bolečega osteoartritisa kolena“, Arthritis & Rheumatism, št. 56, 2007, str. 4055-4064. 3.
English: Lequesne M, Berdah L, Gérentes I. Efficacy and Safety of Diacerein for the treatment of Knee and Hip Osteoarthritis [Efficacité et tolérance de la diacerhéine dans le traitment de la gonarthrose et de la coxarthrose].
Slovenian: Lequesne, M., Berdah, L., Gérentes, I., „Učinkovitost in varnost diacereina pri zdravljenju osteoartritisa kolena in kolka“ [Efficacité et tolérance de la diacerhéine dans le traitment de la gonarthrose et de la coxarthrose], La Revue du Praticien, št. 48, 1998, str. S31-S35.
English: Contact your doctor if you have symptoms of liver problems.
Slovenian: Če imate simptome težav z jetri, se posvetujte z zdravnikom;
English: Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir M A, Choquette D, et al. Efficacy and Safety of Diacerein in Osteoarthritis of the Knee.
Slovenian: Pelletier, J. P., Yaron, M., Haraoui, B., Cohen, P., Nahir, M. A., Choquette, D. in sod., „Učinkovitost in varnost diacereina pri osteoartritisu kolena“, Arthritis and Rheumatism, št. 43 (10), 2000, str. 2339-2348. 5.
English: Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee.
Slovenian: Singh, K., Sharma, R., Rai, J., „Diacerein kot dodatek k natrijevemu diklofenakatu pri osteoartritisu kolena“, International Journal of Rheumatic Diseases, št. 15 (1), 2012, str. 69-77. 4.
English: Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip.
Slovenian: Nguyen, M., Dougados, M., Berdah, L., Amor, B., „Diacerein pri zdravljenju osteoartritisa kolka“, Arthritis Rheum, št. 37 (4), april 1994, str. 529-36.
English: (Invented)name Strength Pharmaceutical Form
Slovenian: (Izmišljeno) ime
English: Immediate Packaging
Slovenian: Velikost pakiranja o ā
English: Invented name Strength Pharmaceutical Form
Slovenian: Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina velikost pakiranja o ā
English: Patients with moderate or severe liver problems should be treated with lower doses.
Slovenian: Bolnike z zmernimi ali hudimi težavami z jetri je treba zdraviti z manjšimi odmerki.
English: Blocking the proteasome system causes the cell to die.
Slovenian: Zaviranje proteasomskega sistema povzroči odmrtje celice.
English: The medicine can only be obtained with a prescription and treatment should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy.
Slovenian: Izdaja zdravila je le na recept, zdravljenje z njim pa se sme uvesti in izvajati samo pod nadzorom zdravnika, ki ima izkušnje z uporabo kemoterapije za zdravljenje raka.
English: If a patient develops severe side effects, treatment must be discontinued, delayed or the dose adjusted.
Slovenian: Če se pri bolniku pojavijo resni neželeni učinki, je treba zdravljenje prekiniti, prestaviti ali prilagoditi odmerek.
English: The full EPAR for Bortezomib Sun can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Bortezomib Sun je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It blocks proteasome, which is a system in cells that breaks down proteins that are no longer needed.
Slovenian: Zavira proteasom, tj. sistem v celicah, ki razgrajuje beljakovine, ko te niso več potrebne.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Bortezomib Sun has been shown to be comparable to Velcade.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Bortezomib Sun primerljivo z zdravilom Velcade.
English: This is a summary of the European public assessment report (EPAR) for Bortezomib Sun.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Bortezomib Sun.
English: The Committee recommended that Bortezomib Sun be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Bortezomib Sun odobri za uporabo v EU.
English: Because Bortezomib Sun is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Bortezomib Sun generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: What measures are being taken to ensure the safe and effective use of Bortezomib Sun?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Bortezomib Sun?
English: When injected under the skin, it is given in the thigh or abdomen (tummy).
Slovenian: Pri injiciranju pod kožo se zdravilo daje v stegno ali abdomen (trebuh).
English: The company that markets Bortezomib Sun will supply educational material to healthcare professionals on making up and giving the injection, calculating the dose, and prescribing and giving the correct treatment for patients receiving blood stem-cell transplantation.
Slovenian: Družba, ki trži zdravilo Bortezomib Sun, bo za zdravstvene delavce zagotovila izobraževalno gradivo o postopku priprave in injiciranja, izračunavanju odmerka ter predpisovanju in izvajanju ustreznega zdravljenja za bolnike, pri katerih bo opravljena presaditev krvotvornih matičnih celic.
English: This means that Bortezomib Sun is similar to a ‘reference medicine' already authorised in the European Union (EU) called Velcade.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Velcade.
English: Other information about Bortezomib Sun
Slovenian: Druge informacije o zdravilu Bortezomib Sun
English: For more information on the use of Bortezomib Sun see the summary of product characteristics (also part of the EPAR).
Slovenian: Za več informacij o uporabi zdravila Bortezomib Sun glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
English: Doses of Bortezomib Sun are given with rest periods between doses, in treatment cycles of three to six weeks depending on whether Bortezomib Sun is given alone or in combination with other medicines.
Slovenian: Odmerki zdravila Bortezomib Sun se dajejo s premori med odmerki, v ciklih zdravljenja, ki trajajo od tri od šest tednov, kar je odvisno od tega, ali se zdravilo Bortezomib Sun daje samostojno ali v kombinaciji z drugimi zdravili.
English: What are the benefits and risks of Bortezomib Sun?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Bortezomib Sun?
English: The recommended dose is calculated using the patient's height and weight).
Slovenian: Priporočeni odmerek se izračuna na podlagi telesne višine in mase bolnika.
English: Bortezomib Sun is a cancer medicine used to treat multiple myeloma, a blood cancer, in the following groups of patients:
Slovenian: Bortezomib Sun je zdravilo proti raku, ki se uporablja za zdravljenje multiplega mieloma, krvnega raka, pri naslednjih skupinah bolnikov:
English: Bortezomib Sun is available in vials as a 3.5 mg powder to be made up into a solution for injection into a vein or under the skin.
Slovenian: Zdravilo Bortezomib Sun je na voljo v vialah v obliki 3,5 -miligramskega praška za pripravo raztopine za injiciranje v veno ali pod kožo.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bortezomib Sun have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo tega zdravila upoštevati zdravstveni delavci in bolniki, so prav tako vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Cancer cells are more sensitive than normal cells to the effects of proteasome inhibitors like bortezomib.
Slovenian: Rakave celice so za učinke zaviralcev proteasoma, kot je bortezomib, občutljivejše od normalnih celic.
English: • adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, blood stem-cell transplantation.
Slovenian: • odraslih, pri katerih se je bolezen poslabšala po vsaj eni drugi obliki zdravljenja in so že opravili presaditev krvotvornih matičnih celic ali pa presaditev pri njih ni mogoča.
English: When given into a vein, the solution is injected through a catheter (a thin sterile tube).
Slovenian: Pri injiciranju v veno se raztopina vbrizga skozi kateter (ozko sterilno cevko).
English: What is Bortezomib Sun and what is it used for?
Slovenian: Kaj je zdravilo Bortezomib Sun in za kaj se uporablja?
English: For practical information about using Bortezomib Sun, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Bortezomib Sun naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: The company provided data from the published literature on bortezomib.
Slovenian: Družba je predstavila podatke o bortezomibu iz objavljene literature.
English: For more information about treatment with Bortezomib Sun, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Bortezomib Sun preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Bortezomib Sun is a ‘generic medicine'.
Slovenian: Zdravilo Bortezomib Sun je „generično zdravilo“.
English: • previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation.
Slovenian: • predhodno nezdravljenih odraslih, ki bodo prejeli kemoterapijo z velikimi odmerki, čemur bo sledila presaditev krvotvornih matičnih celic.
English: Bortezomib Sun is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation.
Slovenian: Zdravilo Bortezomib Sun se uporablja tudi za zdravljenje limfoma plaščnih celic, tj. še ene vrste krvnega raka, pri predhodno nezdravljenih odraslih, pri katerih presaditev krvotvornih matičnih celic ni mogoča.
English: The active substance in Bortezomib Sun, bortezomib, is a proteasome inhibitor.
Slovenian: Zdravilna učinkovina zdravila Bortezomib Sun, bortezomib, je zaviralec proteasoma.
English: • previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation.
Slovenian: • predhodno nezdravljenih odraslih, ki jih ni mogoče zdraviti s kemoterapijo z velikimi odmerki s sočasno presaditvijo krvotvornih matičnih celic.
English: At least 72 hours must pass between two doses of Bortezomib Sun.
Slovenian: Med dvema zaporednima odmerkoma zdravila Bortezomib Sun mora miniti vsaj 72 ur.
English: Therefore, the CHMP's view was that, as for Velcade, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da njegove koristi enako kot pri zdravilu Velcade odtehtajo znana tveganja.
English: Bortezomib Sun must not be given by other routes.
Slovenian: Zdravilo Bortezomib Sun se bolniku ne sme dati na noben drug način.
English: In these patients, Bortezomib Sun is used in combination with melphalan and prednisone;
Slovenian: Pri teh bolnikih se zdravilo Bortezomib Sun uporablja v kombinaciji z melfalanom in prednizonom;
English: For mantle cell lymphoma, Bortezomib Sun is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
Slovenian: Za zdravljenje limfoma plaščnih celic se zdravilo Bortezomib Sun uporablja v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom in prednizonom.
English: Bortezomib Sun is either used on its own in these patients or in combination with pegylated liposomal doxorubicin or dexamethasone;
Slovenian: Zdravilo Bortezomib Sun se pri teh bolnikih uporablja samostojno ali v kombinaciji s pegiliranim liposomalnim doksorubicinom ali deksametazonom;
English: Why is Bortezomib Sun approved?
Slovenian: Zakaj je bilo zdravilo Bortezomib Sun odobreno?
English: No additional studies were needed as Bortezomib Sun is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Velcade.
Slovenian: Ker je zdravilo Bortezomib Sun generično zdravilo, ki se daje z injekcijo in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Velcade, niso bile potrebne nobene dodatne študije.
English: How does Bortezomib Sun work?
Slovenian: Kako zdravilo Bortezomib Sun deluje?
English: In this group of patients, Bortezomib Sun is used in combination with dexamethasone, or with dexamethasone plus thalidomide.
Slovenian: Pri tej skupini bolnikov se zdravilo Bortezomib Sun uporablja v kombinaciji z deksametazonom ali pa z deksametazonom in talidomidom.
English: How has Bortezomib Sun been studied?
Slovenian: Kako je bilo zdravilo Bortezomib Sun raziskano?
English: Bortezomib Sun contains the active substance bortezomib.
Slovenian: Zdravilo Bortezomib Sun vsebuje zdravilno učinkovino bortezomib.
English: How is Bortezomib Sun used?
Slovenian: Kako se zdravilo Bortezomib Sun uporablja?
English: It is not intended to provide practical advice on how to use Bortezomib Sun.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: By 25th November 2013 at the latest
Slovenian: Najkasneje do 25. novembra 2013
English: Within 30 days after CMDh agreement
Slovenian: V 30 dneh od sporazuma skupine CMDh
English: The products with only obstetric indications and for which revocation is applicable (instead of variation to the terms of the marketing authorisation) should be recalled from the market by the Marketing Authorisation Holders by 25th November 2013 at the latest.
Slovenian: Zdravila, ki so odobrena samo za indikacije v porodništvu in za katera velja razveljavitev dovoljenja za promet (namesto spremembe pogojev dovoljenja za promet), morajo imetniki dovoljenj za promet odpoklicati s trga najkasneje do 25. novembra 2013.
English: DHPC Communication circulation according to the CMDh agreed communication plan and conditions.
Slovenian: Razdelitev neposrednih obvestil zdravstvenim delavcem v skladu z načrtom obveščanja in pogoji, ki jih je potrdila skupina CMDh.
English: National Competent Authorities (NCAs) of Member States or Reference Member States (RMS) where applicable, shall ensure that the following conditions are fulfilled by the MAH(s):
Slovenian: Pristojni nacionalni organi držav članic ali referenčnih držav članic, če je to ustrezno, bodo zagotovili, da imetnik(i) dovoljenja za promet z zdravilom izpolnjuje(jo) naslednje pogoje:
English: Annex IV Conditions to the marketing authorisation
Slovenian: Priloga IV Pogoji dovoljenja za promet z zdravilom
English: Conditions to the marketing authorisation
Slovenian: Pogoji dovoljenja za promet z zdravilom
English: The detailed grounds for re-examination were submitted on 2 May 2012.
Slovenian: Podrobna obrazložitev ponovnega pregleda je bila predložena dne 2. maja 2012.
English: in which D is the number of molecules.
Slovenian: v kateri je D število molekul.
English: It should be noted that the present referral procedure focuses on consumer safety.
Slovenian: Treba je poudariti, da se ta napotitev osredotoča na varnost potrošnika.
English: It is assumed that the recommendations are sufficiently conservative to overcome any concerns relating to these issues.
Slovenian: Predpostavlja se, da so priporočila dovolj konservativna, da odpravijo vse zadržke v zvezi s temi vprašanji.
English: Approach taken by CVMP
Slovenian: Pristop odbora CVMP
English: Based on the considerations above the Committee concluded that a conservative recommendation would be appropriate.
Slovenian: Odbor je na podlagi zgornjih utemeljitev zaključil, da je primerno konservativno priporočilo.
English: The evaluation detailed in this opinion attempts to address the issue raised by the European Commission on the basis of the available data.
Slovenian: Vrednotenje, ki je podrobno opisano v tem mnenju, skuša na podlagi razpoložljivih podatkov obravnavati vprašanje, ki ga je sprožila Evropska komisija.
English: While the general nature of the recommendations has its limitations, the approach used aims to provide pragmatic use of limited resources.
Slovenian: Čeprav ima posplošena narava priporočil omejitve, je cilj uporabljenega pristopa pragmatična izraba omejenih virov.
English: These are presented in the table below.
Slovenian: Ta priporočila so prikazana v spodnji preglednici.
English: The longest half-life reported for marker residue was 25 days.
Slovenian: Najdaljša objavljena razpolovna doba označevalnega ostanka je bila 25 dni.
English: This time period can be rounded up to 1 year.
Slovenian: Ta čas lahko zaokrožimo na 1 leto.